NERx 505

Drug Profile

NERx 505

Alternative Names: NERx-505

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NERx Biosciences
  • Class Small molecules
  • Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Bioscience pipeline, September 2016)
  • 27 Sep 2016 NERx Biosciences receives SBIR grant from National Cancer Institute for NERx 505 development in Cancer before September 2016 (NERx pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top